14-day Premium Trial Subscription Sign Up For FreeGet Free

Alnylam Pharmaceuticals Stock Forecast NASDAQ:ALNY

Price Target and Analyst Ratings

Most Recent Rating

On August 27, 2021 "BMO Capital Markets" gave "$174.00 - $196.00" rating for ALNY. The price target was set to $207.63+2.6%.

Last 30 Days

Historical Ratings

Date Rating Action Authority Current Price Target Price
2021-08-27 $174.00 - $196.00 Target Raised by BMO Capital Markets $203.93 $207.63+2.6%
2021-08-13 $235.00 - $250.00 Target Raised by HC Wainwright $196.54 $200.92→1.0%
2021-08-04 $190.00 Reiterated by Chardan Capital $183.44 $182.33+2.0%
2021-08-04 $224.00 - $234.00 Target Raised by Morgan Stanley $183.44 $178.81+0.5%
2021-08-04 $196.00 - $216.00 Target Raised by Barclays $183.44 $178.81+0.5%
2021-08-04 $45.00 - $47.00 Downgraded by Piper Sandler $183.44 $178.81+0.5%
2021-07-16 $205.00 - $224.00 Target Raised by Morgan Stanley $177.54 $173.67+1.0%
2021-05-06 Overweight Target Lowered by Morgan Stanley $132.10 $206.00 → $205.00
2021-04-30 Overweight Target Lowered by Morgan Stanley $140.64 $206.00 → $205.00
2021-04-30 Overweight Target Lowered by Morgan Stanley $140.64 $206.00 → $205.00
2021-04-20 Buy Reiterated by Needham & Company LLC $136.03
2021-03-01 Buy - Neutral Reiterated by Guggenheim $148.75 $162.00
2021-02-22 Buy - Neutral Downgraded by Guggenheim $148.07
2021-02-22 Buy - Neutral Downgraded by Guggenheim $148.07 $162.00
2021-02-14 Hold Reiterated by Royal Bank of Canada $157.92
2021-02-12 Buy Target Raised by Needham & Company LLC $157.92 $160.00 → $180.00
2021-02-12 Overweight Target Raised by Morgan Stanley $157.92 $203.00 → $206.00
2021-02-12 Buy Target Raised by HC Wainwright $157.92 $225.00 → $235.00
2021-02-12 Buy - Neutral Downgraded by Citigroup $157.92 $170.00 → $175.00
2021-02-12 Overweight Target Raised by Barclays $157.92 $162.00 → $196.00
2021-02-12 Buy Reiterated by HC Wainwright $157.92 $225.00 → $235.00
2021-01-25 Outperform - Market Perform Downgraded by BMO Capital Markets $175.69 $185.00
2021-01-13 In-Line - Outperform Target Raised by Cowen $170.93 $154.00 → $197.00
2021-01-08 Buy Reiterated by HC Wainwright $146.66 $225.00
2020-12-21 Sector Perform Target Lowered by Royal Bank of Canada $139.43 $150.00 → $144.00
2020-12-17 Overweight Target Raised by Piper Sandler $138.65 $169.00 → $181.00
2020-12-17 Overweight Reiterated by Piper Sandler $138.65 $169.00 → $181.00
2020-11-25 Target Raised by BMO Capital Markets $125.45 $182.00 → $183.00
2020-11-25 Overweight Target Raised by Morgan Stanley $125.45 $200.00 → $203.00
2020-11-24 Market Perform Target Raised by SVB Leerink $125.66 $90.00 → $91.00
2020-11-06 Overweight Target Raised by Morgan Stanley $130.73 $197.00 → $200.00
2020-10-15 Buy Target Lowered by Bank of America $143.94 $160.00 → $157.00
2020-10-12 Buy Reiterated by Chardan Capital $147.00
2020-09-30 Hold Reiterated by Oppenheimer $145.60 $156.00
2020-09-30 Hold Initiated by Berenberg Bank $145.60
2020-09-08 Buy Initiated by Citigroup $122.99 $170.00 → $170.00
2020-08-11 Outperform - Market Perform Downgraded by Oppenheimer $136.61 $162.00 → $156.00
2020-08-07 Market Perform Target Raised by SVB Leerink $143.53 $89.00 → $90.00
2020-08-07 Buy Reiterated by Chardan Capital $143.53
2020-08-07 Overweight Target Lowered by Morgan Stanley $143.53 $199.00 → $197.00
2020-07-20 Outperform Target Raised by BMO Capital Markets $165.49 $173.00 → $196.00
2020-07-15 Overweight Target Raised by Morgan Stanley $158.02 $162.00 → $199.00
2020-05-28 Neutral Target Raised by UBS Group $133.10 $111.00 → $122.00
2020-05-12 Sector Perform Initiated by Royal Bank of Canada $144.19
2020-05-07 Overweight Target Raised by Barclays $141.45 $143.00 → $156.00
2020-05-07 Outperform Target Raised by BMO Capital Markets $141.45 $145.00 → $171.00
2020-05-07 Outperform Target Raised by Oppenheimer $141.45 $140.00 → $162.00
2020-05-07 Overweight - Neutral Downgraded by JPMorgan Chase & Co. $141.45 $133.00 → $137.00
2020-05-07 Overweight Target Raised by Morgan Stanley $141.45 $148.00 → $162.00
2020-05-06 Buy Target Raised by Needham & Company LLC $145.27 $135.00 → $160.00
2020-04-14 Target Raised by Cantor Fitzgerald $120.72 $195.00 → $202.00
2020-04-14 Target Lowered by Piper Sandler $120.72 $147.00 → $142.00
2020-04-14 Buy Reiterated by Needham & Company LLC $120.72 $135.00
2020-04-14 Reduce Target Lowered by Nomura $120.72 $75.00 → $74.00

ALNY Stock Trend

The stock lies in the lower part of a wide and strong rising trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at $187.30 is broken, it will firstly indicate a slower rate of rising, but may also be an early warning for a trend shift.

Given the current short-term trend, the stock is expected to rise 16.71% during the next 3 months and, with a 90% probability hold a price between $218.59 and $257.67 at the end of this 3-month period.

Data

Date Bottom Mid Top
2021-09-20 $187.80 $204.54 $221.28
2021-09-21 $188.30 $205.04 $221.78
2021-09-22 $188.80 $205.54 $222.28
2021-09-23 $189.30 $206.04 $222.78
2021-09-24 $189.80 $206.54 $223.28
2021-09-27 $190.31 $207.05 $223.78
2021-09-28 $190.81 $207.55 $224.29
2021-09-29 $191.31 $208.05 $224.79
2021-09-30 $191.81 $208.55 $225.29
2021-10-01 $192.31 $209.05 $225.79
2021-10-04 $192.81 $209.55 $226.29
2021-10-05 $193.32 $210.06 $226.79
2021-10-06 $193.82 $210.56 $227.30
2021-10-07 $194.32 $211.06 $227.80
2021-10-08 $194.82 $211.56 $228.30
2021-10-11 $195.32 $212.06 $228.80
2021-10-12 $195.82 $212.56 $229.30
2021-10-13 $196.33 $213.07 $229.81
2021-10-14 $196.83 $213.57 $230.31
2021-10-15 $197.33 $214.07 $230.81
2021-10-18 $197.83 $214.57 $231.31
2021-10-19 $198.33 $215.07 $231.81
2021-10-20 $198.83 $215.57 $232.31
2021-10-21 $199.34 $216.08 $232.82
2021-10-22 $199.84 $216.58 $233.32
2021-10-25 $200.34 $217.08 $233.82
2021-10-26 $200.84 $217.58 $234.32
2021-10-27 $201.34 $218.08 $234.82
2021-10-28 $201.84 $218.58 $235.32
2021-10-29 $202.35 $219.09 $235.83

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. The company’s clinical development programs include Patisiran and Revusiran, which are in Phase III clinical trials for the treatment of transthyretin amyloidosis (ATTR); ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR for the treatment of various forms of ATTR amyloidosis; Fitusiran, an... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 95.000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT